Key result
Sulphinpyrazone reduces CPK release and improves contractility recovery in isolated rat hearts during ischemia-reperfusion.
Why the study?
The direct protective effect of sulphinpyrazone on ischaemic and reperfused hearts and its dependence on concentration was unclear.
Does sulphinpyrazone reduce CPK efflux and improve functional recovery in ischaemic and reperfused rat isolated hearts?
Does sulphinpyrazone reduce CPK efflux and improve functional recovery in ischaemic and reperfused rat isolated hearts?
Sulphinpyrazone exerts a direct, concentration-dependent protective effect on the isolated rat heart during ischaemia and reperfusion by reducing myocardial injury and improving mechanical function.
Supports direct protection in isolated hearts; hypothesis-generating for clinical ischemia-reperfusion injury.
Initiation of 60 min ischaemia to rat isolated hearts produced a depression in developed tension and heart rate. Subsequent reperfusion caused a greatly exacerbated creatine phosphokinase (CPK) efflux and limited functional recovery. Sulphinpyrazone (100 ng ml-1 and 1 microgram ml-1) significantly reduced CPK release, particularly after reperfusion, the lower concentration being more effective. A reduction in the mechanical depression during ischaemia and enhanced recovery after reperfusion were seen only with 100 ng ml-1 sulphinpyrazone. Heart rate and coronary perfusion pressure were unaffected by drug treatment. The reduction in reperfusion-induced CPK efflux by 100 ng ml-1 sulphinpyrazone was maximal when the drug was present throughout the perfusion period although some protection was evident when sulphinpyrazone was present either during ischaemia or reperfusion only. An enhanced recovery in contractility was seen only when the drug was present throughout all phases of perfusion. It is suggested that sulphinpyrazone exerts a direct protective effect on the heart particularly during reperfusion. The degree of protection is critically dependent on the concentration of sulphinpyrazone.
No takes yet. Share an insight, caveat, or question.
Morris Karmazyn (1984) studied Ischaemia and reperfusion. Sulphinpyrazone vs. Untreated control was evaluated on Creatine phosphokinase (CPK) efflux and functional recovery. Sulphinpyrazone (particularly at 100 ng ml-1) significantly reduced creatine phosphokinase release and enhanced recovery of contractility in isolated rat hearts during ischaemia and reperfusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: